“European Union (EU) regulatory clearance is a strategic milestone for CeMines. While this event clearly represents an essential ‘validation’ of our molecular diagnostic technology, it also serves as a vital catalyst, enabling CeMines to proceed with final preparations necessary to commercialize this ‘first to market’ product from our CellCorrect family of molecular diagnostic kits. Simply stated, CeMines will soon offer physicians across Europe a broader range of less invasive Dx tools to assist them in detection and diagnosis of cancer.”
